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Abstract	  1	  
Muscle	  carnosine	  loading	  through	  chronic	  oral	  beta-­‐alanine	  supplementation	  has	  been	  shown	  to	  be	  2	  
effective	   for	   short-­‐duration,	   high-­‐intensity	   exercise.	   This	   randomised,	   placebo	   controlled	   study	  3	  
explored	  whether	   the	   ergogenic	   effect	   of	   beta-­‐alanine	   supplementation	   is	   also	   present	   for	   longer	  4	  
duration	   exercise.	   Subjects	   (27	   well-­‐trained	   cyclists/triathletes)	   were	   supplemented	   with	   either	  5	  
beta-­‐alanine	  or	  placebo	  (6.4	  g/day)	  for	  six	  weeks.	  Time	  to	  completion	  and	  physiological	  variables	  for	  6	  
a	  1-­‐h	  cycling	   time-­‐trial	  were	  compared	  between	  pre-­‐	  and	  post-­‐supplementation.	  Muscle	  carnosine	  7	  
concentration	   was	   also	   assessed	   via	   proton	   magnetic	   resonance	   spectroscopy	   before	   and	   after	  8	  
supplementation.	   Following	   beta-­‐alanine	   supplementation,	   muscle	   carnosine	   concentration	   was	  9	  
increased	  by	  143	  ±	  151%	  (mean	  ±	  SD;	  p	  <	  0.001)	  in	  the	  gastrocnemius	  and	  161	  ±	  56%	  (p	  <	  0.001)	  in	  10	  
the	   soleus.	   Post-­‐supplementation	   time	   trial	   performance	   was	   significantly	   slower	   in	   the	   placebo	  11	  
group	  (60.6	  ±	  4.4	  to	  63.0	  ±	  5.4	  min;	  p	  <	  0.01)	  and	  trended	  towards	  a	  slower	  performance	  following	  12	  
beta-­‐alanine	   supplementation	   (59.8	   ±	   2.8	   to	   61.7	   ±	   3.0	  min;	   p	   =	   0.069).	  We	   found	   an	   increase	   in	  13	  
lactate/proton	   concentration	   ratio	   following	   beta-­‐alanine	   supplementation	   during	   the	   time-­‐trial	  14	  
(209.0	   ±	   44.0	   (beta-­‐alanine)	   vs.	   161.9	   ±	   54.4	   (placebo);	   p	   <	   0.05),	   indicating	   that	   a	   similar	   lactate	  15	  
concentration	  was	  accompanied	  by	  a	   lower	  degree	  of	   systemic	  acidosis,	  even	   though	   this	  acidosis	  16	  
was	   quite	   moderate	   (pH	   ranging	   from	   7.30-­‐7.40).	   In	   conclusion,	   chronic	   beta-­‐alanine	  17	  
supplementation	   in	   well-­‐trained	   cyclists	   had	   a	   very	   pronounced	   effect	   on	   muscle	   carnosine	  18	  
concentration	   and	   a	   moderate	   attenuating	   effect	   on	   the	   acidosis	   associated	   with	   lactate	  19	  
accumulation,	  yet	  without	  affecting	  1-­‐h	  time-­‐trial	  performance	  under	  laboratory	  conditions.	  20	  




	   3	  
Introduction	  1	  
Synthesised	   from	   beta-­‐alanine	   and	   histidine,	   carnosine	   (β-­‐alanyl-­‐L-­‐histidine)	   is	   present	   in	   high	  2	  
concentrations	  within	  human	   skeletal	  muscle	   (Boldyrev,	  Aldini,	  &	  Derave,	   in	  press).	   This	  dipeptide	  3	  
has	  an	  important	  role	  in	  maintaining	  homeostasis	  in	  the	  muscle	  due	  to	  its	  pH	  buffering	  and	  calcium	  4	  
sensitizing	   properties	   (Derave,	   Everaert,	   Beeckman,	   &	   Baguet,	   2010;	   Dutka,	   Lamboley,	   McKenna,	  5	  
Murphy,	  &	  Lamb,	  2012).	  Potential	  additional	  roles	  of	  carnosine	  in	  myocytes,	  such	  as	  antioxidant	  and	  6	  
metal-­‐chelating	  capacity,	  are	  still	  to	  be	  demonstrated.	  7	  
As	  muscle	   carnosine	   synthesis	   is	   rate-­‐limited	   by	   beta-­‐alanine	   (Harris	   et	   al.,	   2006),	   supplementing	  8	  
with	  beta-­‐alanine	  (4-­‐6	  g/day)	  has	  been	  reported	  to	  increase	  muscle	  carnosine	  concentrations	  by	  40-­‐9	  
60%	  after	  4	  weeks	  and	  80%	  by	  10	  weeks.	  These	  increases	  were	  accompanied	  by	  an	  increase	  in	  total	  10	  
work	   done	   in	   a	   high-­‐intensity,	   cycling	   capacity	   test	   (CCT110%)	   by	   13%	   and	   18%	   respectively	   in	  11	  
physically	  active	  students	  (Hill	  et	  al.,	  2007).	  	  12	  
Trained	  sprinters	  have	  higher	  muscle	  carnosine	  concentration	  compared	  to	  untrained	  individuals	  as	  13	  
they	  have	  a	  higher	  proportion	  of	  fast-­‐twitch	  muscle	  fibers	  (Baguet,	  Everaert,	  De	  Naeyer,	  et	  al.,	  2011;	  14	  
Parkhouse,	  McKenzie,	  Hochachka,	  &	  Ovalle,	  1985).	  Beta-­‐alanine	   supplementation	   for	  4	  weeks	   (4.8	  15	  
g/day)	  showed	  increased	  carnosine	  concentration	  by	  37%	  and	  47%	  in	  the	  gastrocnemius	  and	  soleus	  16	  
muscles	   in	   trained	   sprinters,	   along	   with	   improved	   performance	   in	   repeated	   maximal	   bouts	   of	  17	  
isokinetic	  knee	  extensions	  (Derave	  et	  al.,	  2007).	  Other	  studies	  have	  also	  shown	  ergogenic	  benefits	  of	  18	  
carnosine	  loading	  on	  a	  30-­‐s	  maximal	  sprint	  at	  the	  end	  of	  a	  simulated	  cycling	  race	  (Van	  Thienen	  et	  al.,	  19	  
2009)	  and	  rowing	  performance	  (Baguet,	  Bourgois,	  Vanhee,	  Achten,	  &	  Derave,	  2010;	  Ducker,	  Dawson,	  20	  
&	  Wallman,	   2012).	  However,	   there	   is	   a	  need	   for	  more	   field-­‐based	   research	   to	   investigate	   if	   these	  21	  
positive	   findings	   from	   laboratory	   tests	   can	   be	   transferred	   into	   real-­‐world	   environments.	   Trained	  22	  
sprinters	  from	  the	  previously-­‐mentioned	  study	  did	  not	  receive	  an	  ergogenic	  effect	  from	  beta-­‐alanine	  23	  
supplementation	  in	  a	  simulated	  400-­‐m	  race	  despite	  attenuating	  fatigue	  in	  isokinetic	  knee	  extensions	  24	  
(Derave	   et	   al.,	   2007).	   Highly-­‐trained	   Australian	   swimmers	   supplemented	  with	   beta-­‐alanine	   for	   10	  25	  
	   4	  
weeks	  were	  also	  unable	  to	  see	  clear	  benefits	  in	  training	  and	  competition	  performance	  (Chung	  et	  al.,	  1	  
2012).	  Conversely,	  Brazilian	  swimmers	  posted	  positive	  benefits	  in	  swimming	  time	  trial	  performance	  2	  
after	  5	  weeks	  of	  beta-­‐alanine	  supplementation	  (Painelli	  et	  al.,	  2013).	  3	  
Most	  exercise	  protocols	   in	  the	  current	  research	  have	  been	  limited	  to	  short	  duration,	  high-­‐intensity	  4	  
exercise	  as	  emphasis	  is	  put	  on	  the	  role	  of	  muscle	  carnosine	  as	  a	  pH	  buffer	  (Harris,	  Marlin,	  Dunnett,	  5	  
Snow,	  &	  Hultman,	  1990;	  Sewell,	  Harris,	  Marlin,	  &	  Dunnett,	  1992).	  All	  15	  studies	  included	  in	  a	  recent	  6	  
meta-­‐analysis	  utilized	  exercise	  protocols	   lasting	  between	  1	  and	  7	  minutes	   (Hobson,	  Saunders,	  Ball,	  7	  
Harris,	  &	  Sale,	  2012).	  Sprint	  exercises	  that	   last	   less	  than	  1	  minute	  probably	  derive	  no	  benefit	   from	  8	  
beta-­‐alanine	   supplementation.	   In	   incremental	   exercise	   testing,	   beta-­‐alanine	   supplementation	   did	  9	  
not	  increase	  VO2max	  in	  both	  sexes	  (Stout	  et	  al.,	  2007;	  Zoeller,	  Stout,	  O'Kroy	  J,	  Torok,	  &	  Mielke,	  2007)	  10	  
but	   was	   able	   to	   increase	   the	   ventilatory	   threshold	   in	   men	   (Stout	   et	   al.,	   2007)	   which	   could	   be	  11	  
indicative	  of	  the	  ergogenic	  potential	  of	  beta-­‐alanine	  in	  exercise	  activities	  beyond	  15	  minutes.	  12	  
In	  addition,	  some	  research	  studies	  have	  been	  able	  to	  establish	  a	  direct	  role	  for	  carnosine	  on	  muscle	  13	  
contractile	   behaviour.	   Australian	   researchers	   first	   investigated	   the	   effect	   of	   carnosine	   on	   the	  14	  
excitation-­‐contraction	  coupling	  process	   in	  mammalian	  skeletal	  muscle	  fibres	  (Dutka	  &	  Lamb,	  2004)	  15	  
following	   positive	   results	   from	   an	   earlier	   study	   on	   frogs	   and	   cod	   (Lamont	   &	   Miller,	   1992).	   They	  16	  
concluded	   that	   carnosine	   augments	   force	   production	   solely	   by	   increasing	   Ca2+	   sensitivity	   in	   the	  17	  
muscle	   contractile	   apparatus	   of	   rats.	   Further	   exploration	   into	   human	   skeletal	  muscle	   also	   yielded	  18	  
positive	   findings	   for	   a	   similar	   role	   of	   carnosine	   in	   increasing	   Ca2+	   sensitivity	   of	   the	   contractile	  19	  
apparatus	   in	   both	  muscle	   fibre	   types	   as	  well	   as	   potentially	   aiding	   Ca2+	   release	   in	   the	   slow-­‐twitch,	  20	  
type	  I	  fibres	  (Dutka	  et	  al.,	  2012).	  Although	  the	  above-­‐mentioned	  studies	  were	  performed	  in	  skinned	  21	  
single	   fibres,	   similar	   conclusions	   were	   drawn	   from	   studies	   on	   contracting	   intact	   skeletal	   muscles	  22	  
(Everaert,	  Stegen,	  Vanheel,	  Taes,	  &	  Derave,	  2013).	  	  23	  
The	  carnosine	  content	  of	  human	  slow-­‐twitch	  muscle	  fibers	  is	  only	  half	  of	  fast-­‐twitch	  fibers	  (Harris	  et	  24	  
al.,	   2006)	   and	   endurance	   athletes,	   with	   a	   predominantly	   slow-­‐twitch	   musculature,	   have	   lower	  25	  
	   5	  
muscle	  carnosine	  concentration	  than	  untrained	  individuals	  (Baguet,	  Everaert,	  De	  Naeyer,	  et	  al.,	  2011;	  1	  
Parkhouse	  et	  al.,	  1985).	  The	  above-­‐mentioned	  study	  of	  Dutka	  et	  al.	   (2012)	  suggests	  that	  carnosine	  2	  
also	   contributes	   to	   contractile	   behaviour	   in	   slow-­‐twitch	   fibers.	   Therefore,	   we	   aim	   to	   investigate	  3	  
whether	  beta-­‐alanine	   supplementation	   can	   increase	  muscle	   carnosine	   stores	   in	  endurance-­‐trained	  4	  
athletes	   and	   whether	   carnosine	   loading	   can	   improve	   their	   endurance	   performance.	   We	  5	  
hypothesized	  that	  muscle	  carnosine	  loading	  would	  improve	  performance	  in	  a	  1-­‐h	  cycling	  time-­‐trial,	  a	  6	  
reliable	  and	  practically	   relevant	  measure	  of	  endurance	  performance	   (Jeukendrup,	   Saris,	  Brouns,	  &	  7	  
Kester,	  1996).	  8	  
Materials	  and	  Methods	  	  9	  
A	  total	  of	  28	  well-­‐trained	  male	  cyclists/triathletes	  volunteered	  to	  participate	  in	  this	  double-­‐blinded	  10	  
study	  and	  were	  recruited	  in	  three	  cohorts	  (Figure	  1).	  These	  subjects	  undertook	  cycling	  training	  for	  an	  11	  
average	  of	  ~8	  h/wk	  and	  participated	  regularly	  in	  amateur	  or	  semi-­‐professional	  competitions.	  Within	  12	  
each	  cohort,	  subjects	  were	  matched	  for	  VO2peak,	  Wmax	  and	  baseline	  muscle	  carnosine	  concentration	  13	  
and	   placed	   into	   two	   equal	   groups.	   An	   independent	   individual,	   not	   involved	   with	   data	   collection,	  14	  
subsequently	   allocated	   subgroups	   of	   each	   cohort	   randomly	   into	   either	   beta-­‐alanine	   (CarnoSynTM,	  15	  
sustained-­‐release	   beta-­‐alanine,	   Natural	   Alternatives	   International,	   San	   Marcos,	   USA)	   or	   placebo	  16	  
(maltodextrin,	   Natural	   Alternatives	   International,	   San	   Marcos,	   USA)	   supplementation.	   The	  17	  
supplement	  batch	  tested	  negative	  for	  contamination	  from	  prohibited	  substances	  by	  an	  independent	  18	  
drug	  surveillance	  laboratory	  (HFL	  Sport	  Science,	  Cambridgeshire,	  UK).	  19	  
The	  supplementation	  protocol	  lasted	  6	  weeks	  and	  involved	  ingesting	  6.4	  g/day	  (two	  800	  mg	  tablets,	  20	  
four	   times	   daily	   at	   least	   two	   hours	   apart)	   of	   beta-­‐alanine	   or	   placebo	   with	   meals	   or	   snacks.	   All	  21	  
supplements	  were	   contained	   in	   sealed	  opaque	   containers	   and	  were	  distributed	   to	   the	   subjects	   at	  22	  
the	  end	  of	  the	  baseline	  testing	  session.	  All	  subjects	  returned	  the	  supplement	  containers	  at	  the	  post-­‐23	  
supplementation	   testing	   session.	   Muscle	   carnosine	   concentration,	   cycling	   time-­‐trial	   performance	  24	  
and	  exercise	  biochemistry	  were	  analysed	  before	  and	  after	  6	  weeks	  of	  supplementation.	  	  25	  
	   6	  
Subjects	  were	  asked	  to	  keep	  a	  training	  diary	  and	  to	  maintain	  similar	   training	   loads	  throughout	  the	  1	  
supplementation	   period	   to	   avoid	   any	   confounding	   factors	   from	   training	   differently.	   A	   short	  2	  
questionnaire	  about	  supplementation	  grouping,	  side	  effects	  and	  any	  difference	  in	  training	  load	  was	  3	  
completed	   after	   the	   post-­‐supplementation	   tests.	   One	   subject	   of	   the	   placebo	   group	   dropped	   out	  4	  
midway	  during	  the	  study,	  citing	  reasons	  of	  lacking	  in	  time	  to	  maintain	  training	  status	  and	  compliance	  5	  
with	  supplementation.	  This	  research	  was	  approved	  by	  the	  local	  ethics	  committee	  (Ghent	  University	  6	  
Hospital,	  Belgium).	  7	  
Preliminary	  incremental	  cycling	  test	  8	  
On	   the	   first	   visit,	   subjects	   were	   screened	   to	   be	   medically	   fit	   before	   performing	   an	   incremental	  9	  
cycling	   protocol	   (Kuipers,	   Keizer,	   Brouns,	   &	   Saris,	   1987)	   to	   exhaustion	   to	   determine	   peak	   oxygen	  10	  
consumption	  (VO2peak)	  and	  maximal	  workload	  (Wmax).	  After	  a	  5-­‐minute	  warm	  up	  at	  100	  W,	  workload	  11	  
was	   increased	  by	  50	  W	  every	  2.5	  minutes	  until	  a	  heart	  rate	  of	  160	  beats	  per	  minute	  was	  reached.	  12	  
The	   workload	   was	   then	   increased	   by	   25	   W	   every	   2.5	   minutes	   until	   volatile	   exhaustion	   or	   when	  13	  
cycling	  cadence	  was	  less	  than	  60	  r.p.m.	  	  14	  
Maximal	  workload	  was	  determined	  using	  the	  following	  equation:	  Wmax	  =	  Wout	  +	  (t/150)	  *	  25,	  where	  15	  
Wout	   is	  the	   last	  completed	  workload	  and	  t	   is	  the	  number	  of	  seconds	  sustained	  in	  the	   last	  workload	  16	  
(Jeukendrup	   et	   al.,	   1996).	   All	   exercise	   tests	   were	   performed	   on	   an	   electrically-­‐braked	   cycling	  17	  
ergometer	   (Lode,	  Groningen,	  Netherlands).	  Oxygen	  consumption	  was	  measured	  continuously	  via	  a	  18	  
computerised	  breath-­‐by-­‐breath	  system	  (Jaeger	  Oxycon	  Pro,	  Hoechberg,	  Germany).	  	  19	  
Cycling	  time-­‐trial	  20	  
Although	  all	  the	  subjects	  were	  accustomed	  to	  cycling	  at	  moderate	  intensities	  for	  extended	  periods,	  a	  21	  
familiarisation	   time-­‐trial	  was	  conducted	  at	   least	  3	  days	  before	  baseline	  data	  collection.	  Endurance	  22	  
cycling	  performance	  was	  determined	  before	  and	  after	  supplementation	  by	  a	  cycling	  time-­‐trial	  with	  23	  
an	  individualised	  amount	  of	  work	  (Work	  =	  0.75	  *	  Wmax	  *	  3600).	  The	  time-­‐trial	  was	  performed	  with	  24	  
	   7	  
the	  ergometer	  set	  up	  in	  linear	  mode	  according	  to	  the	  following	  formula:	  W	  =	  L	  *	  (r.p.m)2,	  where	  the	  1	  
linear	  factor	  (L)	  is	  calculated	  from	  the	  subject’s	  preferred	  cadence	  (r.p.m)	  at	  75%	  Wmax	  (Jeukendrup	  2	  
et	   al.,	   1996).	   In	   summary,	   they	  would	   be	   able	   to	   complete	   the	   time-­‐trial	   in	   exactly	   1-­‐hour	   if	   they	  3	  
cycled	  constantly	  at	  their	  preferred	  cadence.	  However,	  all	  subjects	  were	  asked	  to	  complete	  the	  time-­‐4	  
trial	  in	  the	  fastest	  time	  possible	  with	  no	  encouragement	  or	  feedback,	  except	  for	  the	  amount	  of	  work	  5	  
completed	  displayed	  on	  the	  computer	  screen.	  Each	  subject	  was	  asked	  to	  refrain	  from	  exercising	  24	  h	  6	  
before	   cycling	   time	   trials	   and	  performed	   the	   time-­‐trials	   at	   the	   same	   time	  of	  day	   in	  pre-­‐	  and	  post-­‐7	  
supplementation	  conditions.	  They	  were	  also	  asked	  to	  avoid	  caffeinated	  products	  and	  to	   ingest	   the	  8	  
same	   pre-­‐exercise	   meals	   2	   hours	   prior	   to	   testing.	   Each	   cycling	   time-­‐trial	   was	   performed	   under	  9	  
laboratory	  conditions	  with	  ad-­‐libitum	  water	  intake.	  10	  
At	  rest,	  25%,	  50%,	  75%	  and	  100%	  of	  the	  cycling	  time	  trial,	  heart	  rate	  (Polar	  RS400,	  Kempele,	  Finland),	  11	  
and	  RPE	  (Borg,	  1982)	  were	  recorded	  and	  blood	  parameters	  of	  pH,	  lactate	  (amperometric	  electrode	  12	  
using	  the	  enzyme,	  lactate	  oxidase)	  were	  determined	  from	  a	  capillary	  blood	  sample	  from	  the	  fingertip	  13	  
with	   an	   automated	   cartridge-­‐based	   gas	   analyser	   (ABL	   90,	   Radiometer,	   Copenhagen,	   Denmark).	  14	  
Blood	  bicarbonate	  was	  calculated	  from	  blood	  pH	  and	  pCO2	  values	  (Henderson-­‐Hasselbach	  equation)	  15	  
while	   proton	   concentration	   was	   calculated	   with	   the	   formula:	   proton	   concentration	   =	   10^(-­‐pH),	  16	  
where	  pH	  is	  blood	  pH	  derived	  from	  the	  capillary	  blood	  sample.	  17	  
The	  coefficient	  of	  variation	  (CV)	  between	  the	  familiarisation	  and	  baseline	  time	  trials	  in	  this	  study	  was	  18	  
3.2%,	  compared	  to	  a	  CV	  of	  3.4%	  from	  the	  original	  validity	  study	  (Jeukendrup	  et	  al.,	  1996).	  19	  
Muscle	  carnosine	  determination	  20	  
Muscle	   carnosine	   concentration	   was	   determined	   non-­‐invasively	   via	   proton	   magnetic	   resonance	  21	  
spectroscopy	   (1H-­‐MRS)	   in	   the	   gastrocnemius	   and	   soleus	   muscles	   as	   described	   by	   Derave	   and	  22	  
colleagues	  (2007).	  Each	  subject	  was	  laid	  supine	  and	  the	  right	  lower	  leg	  was	  fixed	  in	  a	  holder	  with	  the	  23	  
ankle	   at	   20°	  of	   plantar	   flexion.	  All	  MRS	  measurements	  were	  performed	  on	  a	  3-­‐T	  whole	  body	  MRI	  24	  
	   8	  
scanner	  (Siemens	  Trio,	  Erlangen,	  Germany)	  equipped	  with	  a	  spherical	  knee	  coil.	  Single-­‐voxel	  point-­‐1	  
resolved	   spectroscopy	   was	   used	   with	   the	   following	   parameters:	   repetition	   time	   (TR)	   =	   2000	  msl;	  2	  
echo	  time	  (TE)	  =	  30	  ms;	  number	  of	  excitations	  =	  128;	  1024	  data	  points;	  spectral	  bandwidth	  =	  1200	  Hz	  3	  
and	  a	  total	  acquisition	  time	  of	  4.24	  min.	  The	  average	  voxel	  size	  of	  the	  gastrocnemius	  and	  soleus	  was	  4	  
40	  mm	  x	  12	  mm	  x	  30	  mm.	  Following	  shimming	  procedures,	  the	  line	  width	  of	  the	  water	  signal	  was	  on	  5	  
average	  25.7	  and	  24.8	  Hz	   for	  gastrocnemius	  and	  soleus,	   respectively.	  A	  500	  ml	  spherical	  container	  6	  
filled	   with	   an	   aqueous	   solution	   of	   20	   mM	   carnosine	   (Sigma-­‐Aldrich)	   was	   used	   as	   an	   external	  7	  
reference	   for	   absolute	   quantification.	   The	   following	   equation	   was	   used	   to	   determine	   the	  8	  
concentration	  of	  C2-­‐H	  (at	  8	  ppm)	  carnosine	  in	  vivo:	  9	  
[Cm]	  =	  [Cr]	  .	  (Sm	  .	  Vr	  .	  CT1r	  .	  CT2r	  .	  Tm)	  /	  (Sr	  .	  Vm	  .	  CT1m	  .	  CT2m	  .	  Tr)	  10	  
[Cm]:	   carnosine	   concentration	   in	   vivo;	   [Cr]:	   carnosine	   concentration	   of	   the	   external	   reference	  11	  
phantom	  (20	  mM);	  Sm	  and	  Sr:	  estimated	  signal	  peak	  areas	  of	  the	  muscle	  and	  reference	  phantom;	  Vm	  12	  
and	   Vr:	   voxel	   volumes	   of	   the	  muscle	   and	   reference	   phantom;	   CT1r,	   CT2r,	   CT1m	   and	   CT2m:	   correction	  13	  
factors	   for	   the	  T1	  and	  T2	  relaxation	  times	   in	   the	  muscle	  and	   in	   the	  reference	  phantom;	  Tm	  and	  Tr:	  14	  
temperatures	  in	  the	  muscle	  and	  in	  the	  reference	  phantom.	  15	  
The	   CV	   for	   repeated	   measurements	   within	   the	   same	   day	   (Ozdemir	   et	   al.,	   2007)	   were	   7.6%	  16	  
(gastrocnemius)	  and	  4.3%	  (soleus),	  while	  the	  biological	  variability	  within	  a	  6	  week	  period	  (Baguet	  et	  17	  
al.,	  2009)	  were	  14.2%	  (gastrocnemius)	  and	  9.8%	  (soleus).	  18	  
Statistical	  analyses	  19	  
A	  repeated	  measures	  ANOVA	  (2	  conditions	  x	  2	  time	  points)	  was	  used	  to	  evaluate	  muscle	  carnosine,	  20	  
cycling	   time-­‐trial	   performance	  with	   “group”	   (beta-­‐alanine	   vs.	   placebo)	   as	   between-­‐subjects	   factor	  21	  
and	   “time”	   (pre-­‐	   vs.	   post-­‐supplementation)	   as	   within-­‐subjects	   factor.	   Repeated	  measures	   ANOVA	  22	  
were	  used	  to	  also	  compare	  power	  output	  (2	  conditions	  x	  8	  time	  points),	  training	  load	  (2	  conditions	  x	  23	  
6	  time	  points);	  heart	  rate,	  RPE	  and	  blood	  parameters	  of	  pH,	  bicarbonate	  and	  lactate	  (2	  conditions	  x	  5	  24	  
	   9	  
time	  points)	  between	  pre-­‐	  and	  post-­‐supplementation.	  An	   independent	   t-­‐test	  was	  used	  to	  evaluate	  1	  
the	   lactate	  vs.	  proton	  concentration	   ratio	  between	  beta-­‐alanine	  and	  placebo	  groups.	  All	   statistical	  2	  
analysis	   was	   performed	   using	   a	   statistical	   package	   (SPSS	   19.0,	   Chicago,	   IL,	   USA).	   Values	   are	  3	  
presented	  as	  means	  ±	  SD	  with	  significance	  assumed	  at	  p	  <	  0.05.	  	  4	  
Results	  5	  
Supplementation	  and	  training	  6	  
All	   supplement	   containers	   were	   returned	   empty	   and	   compliance	   was	   verbally	   confirmed	   by	   all	  7	  
subjects.	   The	   sustained-­‐release	   formula	   of	   the	   beta-­‐alanine	   supplementation	   was	   not	   tested	   but	  8	  
there	   were	   no	   reports	   of	   paraesthesia	   from	   any	   subjects.	   From	   the	   questionnaire,	   10	   out	   of	   14	  9	  
subjects	  in	  the	  beta-­‐alanine	  group	  and	  12	  out	  of	  13	  subjects	  in	  the	  placebo	  group	  thought	  that	  they	  10	  
were	  supplemented	  with	  placebo.	  11	  
There	   were	   no	   significant	   differences	   between	   groups	   in	   training	   load	   (p	   >	   0.05),	   quantified	   by	  12	  
distance	   or	   duration	   spent	   in	   moderate-­‐high	   intensity	   (Table	   1).	   Qualitatively,	   from	   the	  13	  
questionnaire,	  7	  subjects	  (4	  beta-­‐alanine	  and	  3	  placebo)	  trained	  more	  during	  the	  study,	  9	  subjects	  (5	  14	  
beta-­‐alanine	  and	  4	  placebo)	  had	  similar	  training	  load	  and	  11	  subjects	  (5	  beta-­‐alanine	  and	  6	  placebo)	  15	  
trained	  less	  during	  the	  study.	  16	  
Muscle	  carnosine	  concentration	  17	  
In	  the	  beta-­‐alanine	  group,	  carnosine	  concentration	  was	  increased	  by	  143	  ±	  147%	  (p	  <	  0.001)	  and	  161	  18	  
±	  60%	  (p	  <	  0.001)	  in	  the	  gastrocnemius	  and	  soleus	  respectively.	  There	  were	  no	  significant	  differences	  19	  
in	   the	   absolute	   increase	   in	   carnosine	   concentration	   between	   the	   gastrocnemius	   and	   soleus	   (p	   =	  20	  
0.347).	  Carnosine	  concentration	  also	  increased	  slightly	  in	  the	  placebo	  group	  by	  25	  ±	  40%	  (p	  =	  0.09)	  in	  21	  
the	  gastrocnemius	  and	  18	  ±	  24%	  (p	  =	  0.05)	  in	  the	  soleus	  (Figure	  2).	  	  22	  
Post	  supplementation	  performance	  23	  
	   10	  
Subjects	   in	   the	   beta-­‐alanine	   group	   tended	   to	   be	   slower	   by	   1.9	  min	   (p	   =	   0.069)	  while	   the	   placebo	  1	  
group	   were	   slower	   by	   2.4	   min	   (p	   <	   0.01)	   in	   the	   post-­‐supplementation	   time-­‐trial.	   These	   slower	  2	  
performances	   were	   matched	   by	   differences	   in	   power	   output	   during	   the	   pre-­‐	   and	   post-­‐3	  
supplementation	  time-­‐trial	   (Figure	  4).	  There	  was	  no	  beneficial	  effect	  of	   treatment	  on	  performance	  4	  
parameters,	   as	   indicated	   by	   the	   lack	   of	   interaction	   effects	   (p	   =	   0.621).	   There	  was	   no	   relationship	  5	  
between	  mean	  change	  in	  muscle	  carnosine	  concentration	  and	  cycling	  time-­‐trial	  performance	  in	  both	  6	  
beta-­‐alanine	   (p	   =	   0.615;	   r	   =	   0.147)	   and	   placebo	   (p	   =	   0.09;	   r	   =	   0.487)	   groups.	   There	  were	   also	   no	  7	  
significant	  differences	   in	  peak	  heart	   rate,	   average	  heart	   rate	   and	  RPE	  between	   the	  pre-­‐	   and	  post-­‐8	  
supplementation	  time-­‐trials	  in	  both	  groups	  (Table	  2).	  	  9	  
Exercise	  biochemistry	  10	  
No	  significant	  differences	  were	  present	  at	  any	  time	  point	  between	  beta-­‐alanine	  and	  placebo	  groups	  11	  
during	   the	   post-­‐supplementation	   time-­‐trial	   for	   blood	   pH,	   bicarbonate	   and	   lactate	   concentrations	  12	  
(Table	  2).	  However,	  higher	  values	  were	  recorded	  in	  both	  groups	  for	  pH	  and	  blood	  bicarbonate	  at	  the	  13	  
end	  of	  the	  post-­‐supplementation	  time-­‐trial	  when	  compared	  to	  pre-­‐supplementation.	  When	  the	  ratio	  14	  
of	   lactate	  (mmol/L)	  over	  proton	  (µmol/L)	  concentrations	  was	  calculated,	  this	  ratio	  was	  significantly	  15	  
higher	   at	   the	   end	   of	   the	   time-­‐trial	   in	   the	   beta-­‐alanine	   compared	   to	   placebo	   group	   post-­‐16	  
supplementation,	  whereas	  both	  groups	  did	  not	  differ	  pre-­‐supplementation	  (see	  figure	  5).	  17	  
Discussion	  18	  
Despite	  the	  large	  increases	  in	  muscle	  carnosine	  concentration,	  there	  was	  no	  ergogenic	  benefit	  with	  6	  19	  
weeks	  of	  beta-­‐alanine	  supplementation	  (total	  dosage	  of	  280	  g)	  on	  1-­‐h	  time-­‐trial	  performance.	  In	  fact,	  20	  
post-­‐supplementation	  cycling	  performance	  in	  both	  the	  beta-­‐alanine	  and	  placebo	  groups	  was	  slightly	  21	  
decreased	   compared	   to	   the	   pre-­‐supplementation	   trial.	   We	   also	   did	   not	   find	   any	   relationship	  22	  
between	  the	  magnitude	  of	  increase	  in	  muscle	  carnosine	  concentration	  and	  the	  change	  in	  time-­‐trial	  23	  
performance.	   To	   our	   knowledge,	   this	   study	   is	   the	   first	   to	   document	   the	   lack	   of	   effect	   of	   beta-­‐24	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supplementation	   on	   an	   actual	   endurance	   exercise	   performance	   test	   as	   previous	   studies	   utilised	  1	  
incremental	  exercise	   tests	   (Stout	  et	  al.,	  2007;	  Zoeller	  et	  al.,	  2007)	  and	  high-­‐intensity	  efforts	  at	   the	  2	  
end	  of	  a	  prolonged	  cycling	  protocol	  (Van	  Thienen	  et	  al.,	  2009).	  3	  
A	   key	   finding	   in	   this	   study	   is	   the	   largest	   ever-­‐reported	   relative	   increase	   in	   muscle	   carnosine	  4	  
concentration	   following	   beta-­‐alanine	   supplementation.	   So	   far,	   the	   highest	   reported	   relative	  5	  
increases	   in	   muscle	   carnosine	   following	   chronic	   beta-­‐alanine	   supplementation	   were	   80-­‐85%	  6	  
following	  10-­‐12	  weeks	  (Del	  Favero	  et	  al.,	  2012;	  Hill	  et	  al.,	  2007).	  We	  now	  document	  an	  increase	  of	  7	  
~150%	   after	   only	   6	   weeks	   of	   supplementation.	   Stellingwerff	   and	   colleagues	   (2012)	   combined	   all	  8	  
published	  data	  into	  one	  analysis	  and	  concluded	  that	  the	  total	  amount	  of	  consumed	  beta-­‐alanine	  is	  9	  
the	  primary	  determinant	  of	   the	  degree	  of	   increase	   in	  muscle	   carnosine.	  The	   relationship	  between	  10	  
consumed	   beta-­‐alanine	   and	   increment	   in	   muscle	   carnosine	   from	   this	   analysis	   would	   predict	   an	  11	  
increase	  of	  60%	  in	  response	  to	  the	  280	  g	  of	  beta-­‐alanine	  ingested	  in	  the	  current	  study,	  which	  is	  far	  12	  
below	  the	  actual	  measured	  increase	  of	  140-­‐160%.	  	  13	  
One	   possible	   explanation	   could	   be	   insulin-­‐related	   as	   subjects	  were	   co-­‐ingesting	   beta-­‐alanine	  with	  14	  
their	  meals.	  A	  recent	  study	  from	  Stegen	  et	  al.	  (2013)	  showed	  that	  carnosine	  loading	  (3.2	  g/day	  for	  6-­‐15	  
7	   weeks)	   was	   more	   pronounced	   when	   beta-­‐alanine	   was	   consumed	   together	   with	   a	   meal	   (64%	  16	  
increase	  in	  carnosine)	  than	  between	  meals	  (41%	  increase	  in	  carnosine).	  Another	  possible	  reason	  for	  17	  
the	  large	  increases	  could	  be	  that	  endurance-­‐trained	  athletes	  have	  lower	  baseline	  muscle	  carnosine	  18	  
concentrations	   (Baguet,	   Everaert,	   Hespel,	   et	   al.,	   2011).as	   a	   given	   absolute	   increase	   in	   carnosine	  19	  
concentration	   will	   evidently	   equate	   to	   a	   larger	   relative	   increase	   with	   a	   low	   baseline	   value.	  20	  
Furthermore,	   recent	  unpublished	   research	   (Bex	   et	   al.,	   2013)	   from	  our	   laboratory	   comparing	  beta-­‐21	  
alanine	   supplementation	  between	   controls	   and	   athletes	   showed	   that	   carnosine	   loading	  was	  more	  22	  
pronounced	  in	  the	  trained	  vs.	  untrained	  muscles	  of	  athletes.	  	  23	  
Although	   our	   results	   at	   first	   sight	   did	   not	   reveal	   any	   meaningful	   differences	   in	   exercise-­‐induced	  24	  
blood	   lactate	   concentration	   and	   pH,	   we	   established	   an	   interesting	   corresponding	   relationship	  25	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between	  blood	  pH	  and	  lactate.	  The	  lactate/proton	  concentration	  ratio	  was	  increased	  following	  beta-­‐1	  
alanine	  supplementation	  (Figure	  5),	  indicating	  that	  a	  similar	  lactate	  concentration	  was	  accompanied	  2	  
by	  an	  attenuated	  degree	  of	  systemic	  acidosis.	  This	  was	  only	  significant	  at	   the	  end	  of	   the	  time-­‐trial	  3	  
where	   the	   highest	   blood	   lactate	   concentrations	   would	   occur	   due	   to	   a	   high-­‐intensity	   finish.	   Our	  4	  
finding	  here	  further	  supports	  the	  evidence	  for	  carnosine	  as	  an	  important	  pH	  buffer,	  with	  functional	  5	  
relevance	  for	  acid-­‐base	  balance	  during	  exercise	  in	  humans	  (Baguet,	  Koppo,	  Pottier,	  &	  Derave,	  2010).	  6	  
Even	  though	  we	  showed	  an	  effect	  of	  carnosine	  loading	  on	  lactic	  acidosis,	  no	  effect	  was	  observed	  on	  7	  
exercise	   performance,	   which	   indicates	   that	   pH	   buffering	   is	   not	   a	   limiting	   or	   performance	  8	  
determining	   factor	   in	   a	   1-­‐h	   cycling	   time-­‐trial.	   Similarly,	   induced	   alkalosis	   via	   sodium	   bicarbonate	  9	  
supplementation	   also	   showed	   no	   ergogenic	   effect	   on	   intense	   endurance	   cycling	   performance	  10	  
(Stephens,	  McKenna,	  Canny,	  Snow,	  &	  McConell,	  2002).	  At	   the	  same	  time,	  our	   results	  may	  suggest	  11	  
that	  alternative	  roles	  of	  carnosine	  on	  muscle	  homeostasis	  and	  function,	  such	  as	  the	  calcium	  release	  12	  
and	   sensitivity,	   although	   not	  measured	   in	   the	   present	   study,	  may	   not	  markedly	   affect	   endurance	  13	  
exercise	   performance.	   Despite	   the	   lack	   of	   a	   direct	   beneficial	   effect	   on	   aerobically	   fuelled	  muscle	  14	  
work,	  the	  aerobic	  athlete	  may	  still	  benefit	  from	  beta-­‐alanine	  supplementation	  as	  a	  way	  to	  augment	  15	  
the	  sprint	  capacity	  during	  or	  at	  the	  end	  of	  aerobic	  events	  (Van	  Thienen	  et	  al.,	  2009).	  16	  
In	   the	   current	   study,	   both	   groups	   displayed	   reduced	   exercise	   performance	   following	  17	  
supplementation.	  In	  the	  post-­‐test,	  they	  started	  at	  the	  same	  power	  output,	  but	  failed	  to	  maintain	  a	  18	  
high	  power	  in	  the	  midsection	  until	  the	  end	  of	  the	  trial.	  This	  is	  likely	  attributable	  to	  a	  lower	  training	  19	  
status,	  as	  heart	  rate	  and	  RPE	  throughout	  the	  time-­‐trial	  was	  unchanged,	  indicating	  similar	  degree	  of	  20	  
perceived	   exertion	   and	  motivation	   to	   attain	  maximal	   results	   in	   the	   post-­‐	   vs.	   pre-­‐supplementation	  21	  
trials.	  	  	  22	  
In	  conclusion,	  chronic	  beta-­‐alanine	  supplementation	  in	  well-­‐trained	  cyclists	  had	  a	  very	  pronounced	  23	  
effect	  on	  muscle	   carnosine	   concentration	  and	  a	  moderate	  attenuating	  effect	  on	   the	   change	   in	  pH	  24	  
associated	   with	   lactate	   accumulation.	   However,	   these	   factors	   did	   not	   affect	   1-­‐h	   cycling	   time-­‐trial	  25	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performance	   within	   laboratory	   settings.	   This	   is	   in	   agreement	   with	   pH	   buffering	   as	   the	   primary	  1	  
mechanism	  explaining	  the	  ergogenic	  effects	  of	  carnosine	  loading.	  Therefore,	  the	  role	  of	  beta-­‐alanine	  2	  
supplementation	  as	  an	  ergogenic	  aid	  is	  probably	  limited	  to	  short	  duration	  (1-­‐15	  min),	  high-­‐intensity	  3	  
exercise.	  4	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Table	  1.	  Weekly	  log	  of	  training	  load	  (distance	  and	  duration)	  spent	  in	  moderate-­‐high	  intensity	  during	  
the	  study	  









(n	  =	  13)	  
299	  ±	  184	   239	  ±	  134	   206	  ±	  139	   186	  ±	  141	   194	  ±	  119	   198	  ±	  174	  
Placebo	  
(n	  =	  12)	  






(n	  =	  13)	  
637	  ±	  324	   524	  ±	  278	   438	  ±	  260	   391	  ±	  220	   387	  ±	  224	   465	  ±	  366	  
Placebo	  
(n	  =	  12)	  
512	  ±	  288	   384	  ±	  273	   481	  ±	  257	   446	  ±	  230	   425	  ±	  260	   534	  ±	  262	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Table	  2.	  Blood	  chemistry	  and	  physiological	  variables	  during	  the	  cycling	  time-­‐trial	  
Time-­‐trial	  completion	  
	   	   	   0%	   25%	   50%	   75%	   100%	  
pH	  
Beta-­‐alanine	  
(n	  =	  14)	  
Pre	   7.404	  ±	  0.016	   7.343	  ±	  0.045	   7.358	  ±	  0.048	   7.374	  ±	  0.043	   7.311	  ±	  0.058	  
Post	   7.405	  ±	  0.023	   7.339	  ±	  0.053	   7.370	  ±	  0.034	   7.389	  ±	  0.027	   7.339	  ±	  0.054*	  
Placebo	  
(n	  =	  11)	  
Pre	   7.396	  ±	  0.015	   7.333	  ±	  0.045	   7.357	  ±	  0.055	   7.381	  ±	  0.041	   7.322	  ±	  0.053	  




(n	  =	  14)	  
Pre	   24.8	  ±	  1.4	   19.9	  ±	  2.7	   20.2	  ±	  3.0	   20.8	  ±	  2.7	   17.9	  ±	  2.2	  
Post	   25.4	  ±	  1.0*	   19.6	  ±	  3.5	   20.6	  ±	  2.6	   21.8	  ±	  2.1	   19.1	  ±	  2.5*	  
Placebo	  
(n	  =	  11)	  
Pre	   25.5	  ±	  1.3	   19.3	  ±	  3.0	   19.9	  ±	  3.5	   21.4	  ±	  3.3	   18.8	  ±	  3.2	  




(n	  =	  14)	  
Pre	   1.5	  ±	  0.4	   7.6	  ±	  3.1	   7.1	  ±	  3.4	   6.2	  ±	  3.2	   10.0	  ±	  2.7	  
Post	   1.4	  ±	  0.2	   8.8	  ±	  4.2	   7.1	  ±	  3.3	   5.7	  ±	  2.8	   9.7	  ±	  2.6	  
Placebo	  
(n	  =	  11)	  
Pre	   1.5	  ±	  0.3	   7.9	  ±	  3.1	   6.8	  ±	  3.1	   5.5	  ±	  2.8	   8.5	  ±	  3.1	  




(n	  =	  14)	  
Pre	   68	  ±	  12	   168	  ±	  9	   170	  ±	  10	   170	  ±	  10	   181	  ±	  6	  
Post	   69	  ±	  11	   168	  ±	  12	   169	  ±	  12	   168	  ±	  12	   181	  ±	  8	  
Placebo	  
(n	  =	  13)	  
Pre	   72	  ±	  8	   170	  ±	  12	   171	  ±	  12	   170	  ±	  14	   181	  ±	  11	  
Post	   71	  ±	  13	   168	  ±	  8	   171	  ±	  10	   171	  ±	  11	   180	  ±	  9	  
RPE	  
Beta-­‐alanine	  
(n	  =	  14)	  
Pre	   6.4	  ±	  0.6	   14.5	  ±	  1.8	   15.9	  ±	  1.7	   16.7	  ±	  1.6	   19.0	  ±	  2.1	  
Post	   6.1	  ±	  0.4	   14.5	  ±	  2.0	   16.0	  ±	  1.9	   17.0	  ±	  1.5	   19.0	  ±	  0.8	  
Placebo	  
(n	  =	  13)	  
Pre	   6.2	  ±	  0.6	   14.6	  ±	  1.7	   16.0	  ±	  1.8	   16.8	  ±	  1.3	   18.8	  ±	  1.2	  
Post	   6.0	  ±	  0.0	   15.0	  ±	  1.6	   16.3	  ±	  1.7	   17.0	  ±	  1.6	   18.8	  ±	  1.4	  
Values	   expressed	   as	   mean	   ±	   SD.	   *	   indicates	   difference	   from	   pre-­‐supplementation	   time-­‐trial	   (p	   <	  
0.05).	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Figure	  1.	  Experimental	  design	  and	  subject	  characteristics.
Assessed	  for	  eligibility	  (n	  =	  28) 




	  and	  baseline	  muscle	  carnosine	  (n	  =	  28) 
Analysed	  performance	  (n	  =	  14	  vs.	  13) 
Analysed	  biochemistry	  (n	  =	  14	  vs.	  11) 
2	  sample	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Figure	  2.	  Pre-­‐	  and	  post-­‐supplementation	  carnosine	  concentration	  in	  gastrocnemius	  and	  soleus	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Figure	  3.	  Time	  to	  complete	  an	   individualised	  cycling	  time-­‐trial	  pre-­‐	  and	  post-­‐supplementation	  with	  
either	  beta-­‐alanine	  or	  placebo.	  *	  indicates	  significant	  difference	  from	  pre-­‐supplementation	  time-­‐trial	  
in	   the	   placebo	   group	   (p	   <	   0.05).	   	   $	   indicates	   approaching	   significant	   difference	   from	   pre-­‐
supplementation	  time-­‐trial	  in	  the	  beta-­‐alanine	  group	  (p	  =	  0.069).	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Figure	  4.	  Power	  output	  during	  cycling	  time-­‐trial	  performance	  before	  and	  after	  6	  weeks	  of	  beta-­‐
alanine	  or	  placebo	  supplementation.	  *	  indicates	  difference	  between	  pre-­‐	  and	  post-­‐supplementation	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Figure	  5.	  Post-­‐supplementation	   lactate	  (mmol/L)	  to	  proton	  (µmol/L)	  concentration	  ratio	  during	  the	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